home / stock / allk / allk news

ALLK News and Press, Allakos Inc. From 10/21/20

Stock Information
Company Name: Allakos Inc.
Stock Symbol: ALLK
Market: NASDAQ
Website: allakos.com
Menu
ALLK ALLK Quote ALLK Short ALLK News ALLK Articles ALLK Message Board
Get ALLK Alerts

News, Short Squeeze, Breakout and More Instantly...
ALLK - Allakos Announces Publication of Results from the Phase 2 Study of Lirentelimab (AK002) in Patients with Eosinophilic Gastritis and/or Eosinophilic Duodenitis (ENIGMA) in the New England Journal of Medicine

REDWOOD CITY, Calif., Oct. 21, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related diseases, today announced the publication of results from the multicenter, randomized, double-bl...
ALLK - Allakos EPS misses by $0.20

Allakos (NASDAQ: ALLK ) : Q2 GAAP EPS of -$0.80 misses by $0.20 . Cash and cash equivalents of $153.89M Press Release More news on: Allakos Inc., Earnings news and commentary, Healthcare stocks news,

ALLK - Allakos Reports Second Quarter 2020 Financial Results and Provides Business Update

REDWOOD CITY, Calif., Aug. 10, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell-related diseases, today reported financial results for the second quarter ended June...

ALLK - Allakos Initiates Patient Recruitment for AK002 Registrational Studies

-- Phase 3 study in eosinophilic gastritis and/or eosinophilic duodenitis and Phase 2/3 study in eosinophilic esophagitis --  -- Top-line safety and efficacy results from both studies expected in the second half of 2021 -- REDWOOD CITY, Calif., June 03, 2020 (GLOBE NEWSWIRE) -...
ALLK - Allakos Announces Multiple Presentations Related to Eosinophil and Mast Cell-Driven Diseases at the Digital EAACI Annual Congress 2020

REDWOOD CITY, Calif., May 21, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antolimab (AK002) for the treatment of eosinophil and mast cell related diseases, today announced the acceptance of two oral abstract presenta...

ALLK - Allakos Announces a Presentation of Antolimab in Patients with Severe Allergic Conjunctivitis at the 2020 ASCRS Virtual Annual Meeting

REDWOOD CITY, Calif., May 11, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antolimab (AK002) for the treatment of eosinophil and mast cell related diseases, today announced the acceptance of an oral presentation at th...

ALLK - Allakos Reports First Quarter 2020 Financial Results

REDWOOD CITY, Calif., May 11, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antolimab (AK002) for the treatment of eosinophil and mast cell-related diseases, today reported financial results for the first quarter ended...
ALLK - HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Alerts Allakos (ALLK) Investors: Important Application Deadline Tomorrow, Investors with Losses Should Contact its Attorneys Now

SAN FRANCISCO, CA / ACCESSWIRE / May 10, 2020 / Hagens Berman urges Allakos Inc. ( NASDAQ:ALLK ) investors who have suffered significant losses to submit their losses now . Tomorrow is the lead plaintiff deadline in a securities fraud class action that has been filed against the company ...

ALLK - HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Updates ALLK, CRON, FNKO Investors: 2-DAY APPLICATION DEADLINE ALERT, Investors with Losses Should Contact Firm Immediately

SAN FRANCISCO, May 09, 2020 (GLOBE NEWSWIRE) -- Hagens Berman updates investors in the following publicly-traded companies and urges investors who have suffered significant losses to contact the firm.  Further details about the cases, including the upcoming May 11, 2020 lead plaintiff...

ALLK - HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Urges Allakos (ALLK) Investors with Losses to Contact Its Attorneys: 4 DAYS to APPLICATION DEADLINE

SAN FRANCISCO, CA / ACCESSWIRE / May 7, 2020 / Hagens Berman urges Allakos Inc. ( NASDAQ:ALLK ) investors who have suffered significant losses to submit their losses now . Only four days remain until the May 11, 2020 lead plaintiff deadline in a securities fraud class action that has been...
Previous 10 Next 10